BioCardia, Inc. (BCDA) stock
BCDANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.92−0.01 (-0.91%)
Close on Nov 11, 2026Market cap $13.95MP/E –Yield –
BioCardia gross margin
Gross margin is gross profit as a percentage of revenue.
BioCardia's gross margin for the twelve months ending Dec 31, 2021 was 100.0%. For fiscal 2021 it was 100.0%, against 97.2% the year before. The highest annual figure on record is 100.0% in fiscal 2011.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2021 | Dec 31, 2021 | 100.0% | +2.8 |
| FY2020 | Dec 31, 2020 | 97.2% | +47.7 |
| FY2019 | Dec 31, 2019 | 49.6% | +32.3 |
| FY2018 | Dec 31, 2018 | 17.3% | +61.3 |
| FY2017 | Dec 31, 2017 | -44.1% | −14.5 |
| FY2016 | Dec 31, 2016 | -29.5% | −12.1 |
| FY2015 | Dec 31, 2015 | -17.4% | −117.4 |
| FY2011 | Dec 31, 2011 | 100.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q4 FY2021 | Dec 31, 2021 | 100.0% | +0.0 |
| Q3 FY2021 | Sep 30, 2021 | 100.0% | +0.0 |
| Q2 FY2021 | Jun 30, 2021 | 100.0% | +10.5 |
| Q4 FY2020 | Dec 31, 2020 | 100.0% | +17.2 |
| Q3 FY2020 | Sep 30, 2020 | 100.0% | +12.4 |
| Q2 FY2020 | Jun 30, 2020 | 100.0% | +222.1 |
| Q1 FY2020 | Mar 31, 2020 | 89.5% | +38.5 |
| Q4 FY2019 | Dec 31, 2019 | 82.8% | +95.4 |
| Q3 FY2019 | Sep 30, 2019 | 87.6% | +117.4 |
| Q2 FY2019 | Jun 30, 2019 | -122.1% | −165.6 |
| Q1 FY2019 | Mar 31, 2019 | 50.9% | +29.8 |
| Q4 FY2018 | Dec 31, 2018 | -12.6% | +52.4 |
| Q3 FY2018 | Sep 30, 2018 | -29.8% | −16.7 |
| Q2 FY2018 | Jun 30, 2018 | 43.5% | +124.8 |
| Q1 FY2018 | Mar 31, 2018 | 21.1% | +48.8 |
| Q4 FY2017 | Dec 31, 2017 | -65.0% | −42.4 |
| Q3 FY2017 | Sep 30, 2017 | -13.1% | +54.4 |
| Q2 FY2017 | Jun 30, 2017 | -81.3% | – |
| Q1 FY2017 | Mar 31, 2017 | -27.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -22.6% | – |
| Q3 FY2016 | Sep 30, 2016 | -67.5% | – |
See a number that looks wrong?